Yogliptin monotherapy in type 2 diabetes: A 12‐week randomized, double‐blind, placebo‐controlled phase II study

BACKGROUND: The new xanthine dipeptidyl peptidase‐4 inhibitor yogliptin has exhibited excellent hypoglycemic activity in experimental disease models. The present work aimed to assess the efficacy of yogliptin as a monotherapy in individuals with type 2 diabetes mellitus (T2DM). METHODS: A 12‐week, d...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xin, Wang, Ying, Yong, Xiaolan, Wu, Bojun, Sun, Zilin, Lou, Ning, Wen, Qing, Zhang, Yufang, Li, Shiyun, Li, Jiarui, He, Yan, Cheng, Jinluo, Zhong, Xiangdong, Shen, Jing, Yang, Wenying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789391/
https://www.ncbi.nlm.nih.gov/pubmed/36515221
http://dx.doi.org/10.1111/1753-0407.13337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789391/
https://www.ncbi.nlm.nih.gov/pubmed/36515221
http://dx.doi.org/10.1111/1753-0407.13337

Ejemplares similares